Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-07-08
2008-07-08
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S224000, C544S238000, C514S252010, C514S252020, C514S252030, C514S252050
Reexamination Certificate
active
07396831
ABSTRACT:
Compounds having the general structureand compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritis, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.
REFERENCES:
patent: 2691655 (1954-10-01), Hitchings et al.
patent: 3707560 (1972-12-01), De Angelis et al.
patent: 4725600 (1988-02-01), Takaya et al.
patent: 5272167 (1993-12-01), Girijavallabhan et al.
patent: 5459144 (1995-10-01), Girijavallabhan et al.
patent: 5461053 (1995-10-01), Boigegrain et al.
patent: 5750532 (1998-05-01), Girijavallabhan et al.
patent: 5916887 (1999-06-01), Singh et al.
patent: 5932590 (1999-08-01), Ciccarone et al.
patent: 5936084 (1999-08-01), Jirousek et al.
patent: 5959123 (1999-09-01), Singh et al.
patent: 5965569 (1999-10-01), Camps Garcia et al.
patent: 5969140 (1999-10-01), Ukita et al.
patent: 6093737 (2000-07-01), Anthony et al.
patent: 6255489 (2001-07-01), Klintz et al.
patent: 6569847 (2003-05-01), Singh et al.
patent: 2002/0137755 (2002-09-01), Bilodeau et al.
patent: 2004/0204386 (2004-10-01), Bhatt et al.
patent: 0 937 459 (1999-01-01), None
patent: 1 300 399 (2003-04-01), None
patent: WO 97/13754 (1997-04-01), None
patent: WO 97/41127 (1997-11-01), None
patent: WO 98/12176 (1998-03-01), None
patent: WO 98/12210 (1998-03-01), None
patent: WO 98/28980 (1998-07-01), None
patent: WO 99/12911 (1999-03-01), None
patent: WO 99/28314 (1999-06-01), None
patent: WO 99/41248 (1999-08-01), None
patent: WO 99/51241 (1999-10-01), None
patent: WO 00/59881 (2000-10-01), None
patent: WO 01/05768 (2001-01-01), None
patent: WO 01/07032 (2001-02-01), None
patent: WO 01/07401 (2001-02-01), None
patent: WO 01/12621 (2001-02-01), None
patent: WO 01/14331 (2001-03-01), None
patent: WO 0142241 (2001-06-01), None
patent: WO 01/74331 (2001-10-01), None
patent: WO 01/76582 (2001-10-01), None
patent: WO 01/87845 (2001-11-01), None
patent: WO 01/93682 (2001-12-01), None
patent: WO 02/00651 (2002-01-01), None
patent: WO 02 04427 (2002-01-01), None
patent: WO 02/12198 (2002-02-01), None
patent: WO 02/18339 (2002-03-01), None
patent: WO 0222605 (2002-03-01), None
patent: WO 02/26712 (2002-04-01), None
patent: WO 02/36586 (2002-05-01), None
patent: WO 02/50052 (2002-06-01), None
patent: WO 02/079197 (2002-10-01), None
patent: WO 02/080853 (2002-10-01), None
patent: WO 02/088111 (2002-11-01), None
patent: WO 03/006471 (2003-01-01), None
patent: WO 03/028729 (2003-04-01), None
patent: WO 03/041649 (2003-05-01), None
patent: WO 03/093242 (2003-11-01), None
patent: WO 2004/005283 (2004-01-01), None
patent: WO 2004/046133 (2004-06-01), None
patent: WO 2004/065378 (2004-08-01), None
patent: WO 2004/089286 (2004-10-01), None
Abstract of Bebbington et al. WO 02/22605 A1 (4 pages).
Matsuda et al. Bioorganic & Medicinal Chemistry Letters (2001), 11(17), 2369-2372.
Valenzano et al. Curr. Med. Chem. 3185-3202, 2004 (PubMed Abstract provided).
Szallasi et al, Journal of Medicinal Chemistry 47(20): 2717-2723, 2004.
Kumar, et al., A Novel and Covenient Syhthesis of 2-Amino-4-(N-alkyl-N-arylamino)-pyrimidines using Polarized Ketene S,S- and S,N-Acetals, Synthesis, 9: 748-751 (1980).
Lee, et al., N-(3-Acloxy-2-benzylpropyl)-N-[4-(methylsufonylamino)benzyl]thiourea Analogues: Novel Potent and High Affinity Antagonists and Partial Antagonists of the Vanilloid Receptor, J Med. Chem., 46: 3116-3126 (2003).
Hajduk, et al., “Novel Inhibitors of Erm Methyltransferases from NMR and Parallel Synthesis” J. Med Chem, 42,19: 3852-3859 (1999).
Harada, et al., WO 02/06237, CA 136: 118474 (2002) (Abstract) (2002).
Zimmermann, et al., Archiv der Pharmazie 329(7): 371-376, )1996) CA 125: 184908, (1996) (Abstract).
Shams, et al., Journal fuer Praktische Chemie (Liepzig) 330(5): 817 (1988), CA 111: 97050 (1988) (Abstract).
El-Sakka, et al., Environmental & Biochemical Problems, 48(2): 7-16 (1995), CA 123: 112011 (1995) (Abstract).
Elkasby, et al., Indian Journal of Chemistry, Section B: 20B(5): 428-431 (1981), CA 95: 150360 (1981) (abstract).
Robev, Heterocycles 14(4) : 461-464 (1980), CA 93: 46364 (1980) (abstract).
Abdalla, et al., Pakistan Journal of Scientific and Industrial Research 20(3): 139-149 (1977), CA 90: 137633 (1977) (Abstract).
Fusco, et al., Gazzetta Chimica taliana 98(5): 511-534 (1968), CA 96:96598 (1968) (Abstract).
Arasasingham Premilla
Chakrabarti Partha P.
Chen Ning
Doherty Elizabeth M.
Fotsch Christopher H.
Amgen Inc.
Habte Kahsay T
Person Richard V.
LandOfFree
Vanilloid receptor ligands and their use in treatments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vanilloid receptor ligands and their use in treatments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vanilloid receptor ligands and their use in treatments will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2808656